Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04007939
Other study ID # PLX-PLMC
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2018
Est. completion date December 31, 2022

Study information

Verified date October 2023
Source Metagenics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

It has been suggested that the best medicine should include four principles (4P) - Medicine should be personalized, predictive, preventative and participatory. Technology has provided the tools to collect data in ways not previously possible. Individuals can now collect information on their genome (including their genetic predisposition to tolerate medications and to respond to healthy lifestyle programs) that will modify their lifestyle and therapeutic choices. Beyond spot checks of vital signs and weight, individuals can now collect information on body composition, continuous monitoring of heart rate, blood pressure, and even blood sugar. Data on food consumption at a caloric, macronutrient and even micronutrient level can be collected. Standard medical histories and detailed physical examination findings and laboratory biomarkers can be correlated with this data. Collections of individual patient data will need to be managed through computer programs and smart phone applications that provide direct feedback about the influence of lifestyle on health, wellness and biomarkers. To this end, Metagenics is designing and is launching a smart phone application, Personal Lifestyle Engine (PLX), for individual use by patients and their healthcare providers. The statistical analysis of these data is the primary objective of this study.


Description:

Technology has led to a significant revisioning and modification of the models of medicine in practice today. It has been suggested that the best medicine should include four principles - Medicine should be personalized, predictive, preventative and participatory. This 4P medicine will thus be patient centered with a focus on the person who has the disease and not the disease the person has. It will be predictive as it identifies the preclinical trend/decline towards illness sooner than onset of symptoms that herald the loss of function and health. It will be preventative as the information gathered should offer opportunities to modify these trajectories towards illness and finally it will be participatory as individuals will be intimately involved in the gathering of data to identify trends and in the application of lifestyle measures to improve the quality of their life. Technology has provided the tools to collect data in ways not previously possible. Individuals can now collect information on their genome (including their genetic predisposition to tolerate medications and to respond to healthy lifestyle programs) that will modify their lifestyle and therapeutic choices. Beyond spot checks of vital signs and weight, individuals can now collect information on body composition, continuous monitoring of heart rate, blood pressure, and even blood sugar. Data on food consumption at a caloric, macronutrient and even micronutrient level can be collected. Standard medical histories and detailed physical examination findings and laboratory biomarkers can be correlated with this data. As has been noted in the Nathan Price et al. article, "A wellness study of 108 individuals using personal, dense, dynamic data clouds" (PMID: 28714965), a significant challenge to the effective use of these complex sets of individual patient data is how to define the boundaries between disease, average health and optimal wellbeing. To meet this challenge, compiling and analyzing collections of de-identified, detailed patient histories, questionnaires regarding symptoms and general condition, and associated objective findings (genomic data, vital signs, and physical exam and laboratory biomarkers) will theoretically identify these boundaries and will facilitate the deliverance of 4P Medicine. Comprehensive data collections on each subject evaluated in aggregate provides a diversity of uniqueness markers that can be statistically probed to identify patterns that predict wellbeing and perhaps individual response to lifestyle interventions. An additional challenge for both the patient and their health care provider in 2018 and beyond is how to manage this data in an effective manner. Collections of individual patient data will need to be managed through computer programs and smart phone applications that provide direct feedback about the influence of lifestyle on health, wellness and biomarkers. To this end, Metagenics is designing and is launching a smart phone application, PLX, for individual use by patients and their healthcare providers. After and while a statistical analysis of this data set has been/is being completed, the data set will also be used in an initial beta test of the PLX operating system. The PLX application will not be used to conduct the statistical analysis which is the primary objective of this study."


Recruitment information / eligibility

Status Completed
Enrollment 400
Est. completion date December 31, 2022
Est. primary completion date December 31, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Male or Female - Ages 18-80, inclusive - Willing to give written informed consent to participate in the study Exclusion Criteria: - A serious, unstable illness including cardiac, hepatic, renal, gastrointestinal, respiratory, endocrinologic, neurologic, immunologic, or hematologic disease. - Known infection with human immunodeficiency virus (HIV), tuberculosis (TB), or hepatitis B or C. - Inability to comply with study and/or follow-up visits. - Any concurrent condition (including clinically significant abnormalities in medical history, physical examination or laboratory evaluations) which, in the opinion of the Principle Investigator (PI), would preclude safe participation in this study or interfere with compliance. - Any sound medical, psychiatric and/or social reason which, in the opinion of the PI, would preclude safe participation in this study or interfere with compliance.

Study Design


Locations

Country Name City State
United States Personalized Lifestyle Medicine Center Gig Harbor Washington

Sponsors (2)

Lead Sponsor Collaborator
Metagenics, Inc. MetaProteomics LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Height measured in meter (m) Baseline
Primary Weight measured in kilogram (kg) Baseline
Primary Body Mass index (BMI) BMI is measured in (weight in kilogram (kg)/ height in meter (m)^2) outcome in double digits. Baseline
Primary Waist Circumference (WC) measured in centimeters (cm) Baseline
Primary Hip Circumference (HC) measured in cm Baseline
Primary Waist-to-Hip Ratio (WHR) WHR is numerical (0.00) and is and indicator for major health risk. Baseline
Primary Glucose Fasting glucose levels measured in blood in milligram/deciLiter (mg/dL) Baseline
Primary Total Cholesterol Fasting total cholesterol level is measured in serum in mg/dL Baseline
Primary Anti-Nuclear Antibodies (ANA) ANA is measured as a titer by serum dilution detects autoimmune disease. Baseline
Primary 25-hydroxy (OH) Vitamin D3 25-OH vitamin D3 is measured in blood in nanogram/milliLiter (ng/mL) and detects deficiencies. Baseline
Primary High sensitivity C-Reactive Protein (Hs-CRP) Hs-CRP is measured in blood in mg/L detects inflammation. Baseline
Primary Homocysteine Homocysteine is measured in serum in micromol/Liter (µmol/L) Baseline
Primary Omega-3 Fatty Acids Omega-3 fatty acids: Eicosapentaenoic (EPA), Docosahexaenoic (DHA), and Docosapentaenoic (DPA) levels are measured in % weight. Baseline
Primary Beck Depression Inventory (BDI) BDI is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression. Rating system: 1-10: These ups and downs are considered normal; 11-16: Mild mood disturbance; 17-20: Borderline clinical depression; 21-30: Severe depression; over 40: Extreme depression Baseline
Primary Beck Anxiety Inventory (BAI) BAI is a multiple-choice self-report inventory that is used for measuring the severity of anxiety in children and adults.The BAI contains 21 questions, each answer being scored on a scale value of 0 (not at all) to 3 (severely). Higher total scores indicate more severe anxiety symptoms. The standardized cutoffs[4] are:
0-7: minimal anxiety 8-15: mild anxiety 16-25: moderate anxiety 26-63: severe anxiety
Baseline
Primary Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Test PROMIS Sleep Disturbance Test is a self-scored test to identify sleep disturbance. Each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of sleep disturbance. The T-scores are interpreted as follows: Less than 55 = None to slight 55.0-59.9 = Mild 60.0-69.9 = Moderate 70 and over = Severe Baseline
Primary Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Test PROMIS Anxiety test is a 7-item questionnaire that assesses the pure domain of anxiety in individuals age 18 and older. Each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 7 to 35 with higher scores indicating greater severity of anxiety. The T-scores are interpreted as follows: Less than 55 = None to slight 55.0-59.9 = Mild 60.0-69.9 = Moderate 70 and over = Severe Baseline
Primary Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Short Form (SF) PROMIS Depression SF is an 8-item questionnaire that assesses the pure domain of depression in individuals age 18 and older. Each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of depression.The T-scores are interpreted as follows: Less than 55 = None to slight 55.0-59.9 = Mild 60.0-69.9 = Moderate 70 and over = Severe Baseline
Primary Genomics DNA polymorphism measured using 23&Me Baseline
Primary Stool Stool analysis measured by a stool analysis kit from American Gut Baseline
See also
  Status Clinical Trial Phase
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04481503 - Transthoracic Echocardiography of Ventricular Function of Parturients in Labor
Terminated NCT04088240 - Effects of Omega-3 Docosapentaenoic Acid on Lipids and Other Risk Factors for Cardiovascular Disease N/A
Completed NCT03410342 - The Effects of Types of Fruits and Vegetables on Vascular Function N/A
Completed NCT03170752 - Implementing and Testing a Cardiovascular Assessment Screening Program (CASP) N/A
Recruiting NCT04231838 - Metabolic Syndrome in Diabetic Smokers Using Cigarettes & Combustion-Free Nicotine Delivery Systems N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Terminated NCT03517111 - The Impact of a Parenting Intervention on Latino Youth Health Behaviors N/A
Completed NCT04562467 - The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk Phase 4
Completed NCT03429920 - Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors N/A
Completed NCT04551872 - RESILIENCE: Personalizing Cardiovascular Health N/A
Enrolling by invitation NCT03314818 - Natural History of Carotid Plaque as Determined by 3D Ultrasound N/A
Completed NCT03060811 - Mediterranean Diet, Trimethylamine N-oxide (TMAO) and Anti-oxidants in Healthy Adults N/A
Completed NCT04279704 - Overcoming Obstacles in Epigenetic Analysis of Human Twins
Completed NCT01050205 - The Healthy Lifestyle Project N/A
Completed NCT03570840 - Pediatric Metabolic Syndrome Study
Completed NCT03039023 - Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans N/A
Completed NCT03646175 - Choline Supplementation and Cardiovascular Health N/A